Nonachlazine is an original drug synthesized in the Institute of Pharmacology, Academy of Medical Sciences of the USSR. The results of clinical trials have shown that Nonachlazine is an antianginal agent distinguished by its high efficacy in the treatment of ischemic heart disease. Experimental studies have shown that an important role in the mechanism of the antianginal effect of nonachlazine is played by its effect on adrenergic processes of regulation of the circulation and cardiac activity. Nonachlazine increases the noradrenalin concentration and activity of phosphorylase "a" in the myocardium. These findings suggest that the beneficial effect of nonachlazine is evidently associated with its ability to activate adrenergic mechanisms in the regulation of glycogenolysis. Yonahlazin is used in patients who do not tolerate nitroglycerin or who have contraindications to its use. Nonahlazin in solution, unlike nitroglycerin, does not lower arterial pressure and does not cause dizziness, but often nitroglycerin more effectively eliminates an attack than Nonachlazine.